B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
| Autor: | Larysa Sanchez, Alexandra Dardac, Deepu Madduri, Shambavi Richard, Joshua Richter |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Hematology, Vol 12 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2040-6215 20406207 |
| DOI: | 10.1177/2040620721989585 |
| Popis: | Outcomes of patients with multiple myeloma (MM) who become refractory to standard therapies are particularly poor and novel agents are greatly needed to improve outcomes in such patients. B-cell maturation antigen (BCMA) has become an important therapeutic target in MM with three modalities of treatment in development including antibody–drug conjugates (ADCs), bispecific T-cell engagers (BITEs), and chimeric antigen receptor (CAR) T-cell therapies. Early clinical trials of anti-BCMA immunotherapeutics have demonstrated extremely promising results in heavily pretreated patients with relapsed/refractory MM (RRMM). Recently, belantamab mafodotin was the first anti-BCMA therapy to obtain approval in relapsed/refractory MM. This review summarizes the most updated efficacy and safety data from clinical studies of BCMA-targeted therapies with a focus on ADCs and BITEs. Additionally, important differences among the BCMA-targeted treatment modalities and their clinical implications are discussed. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|